Bioo Scientific Releases new T3™ Conjugation Kit
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Bioo Scientific has announced the release of its new T3™ Conjugation Kit, which is designed for scientists to specifically target any cell type for silencing with RNAi. It can be used in vivo or with primary cell lines in vitro.
The T3 Conjugation Kit offers effective in vivo delivery of siRNA and miRNA targeted to almost any cell or tissue. This technology reduces the chance of off target effects since the systemically delivered siRNA vehicle locates and targets specific cells and tissues reducing the amount of siRNA required for silencing.
The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cell lines consisting of mixed cell populations. The patent pending T3 technology functions by conjugating a T3 Carrier to an antibody that can identify a receptor or other extracellular domain specific to the targeted cell or tissue type.
The T3 Carrier-Antibody conjugate may then be loaded with siRNA and delivered systemically or locally in vivo or in vitro. Targeted cells or tissues then take up the T3 Conjugate and the siRNA is released.
The T3 Conjugation Kit offers effective in vivo delivery of siRNA and miRNA targeted to almost any cell or tissue. This technology reduces the chance of off target effects since the systemically delivered siRNA vehicle locates and targets specific cells and tissues reducing the amount of siRNA required for silencing.
The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cell lines consisting of mixed cell populations. The patent pending T3 technology functions by conjugating a T3 Carrier to an antibody that can identify a receptor or other extracellular domain specific to the targeted cell or tissue type.
The T3 Carrier-Antibody conjugate may then be loaded with siRNA and delivered systemically or locally in vivo or in vitro. Targeted cells or tissues then take up the T3 Conjugate and the siRNA is released.
